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ORIGINAL ARTICLE
BACKGROUND: Amid national efforts to improve the quality of care for 
people with cardiovascular disease in China, the use of traditional Chinese 
medicine (TCM) is increasing, yet little is known about its use in the early 
management of acute myocardial infarction (AMI).
METHODS AND RESULTS: We aimed to examine intravenous use of 
TCM within the first 24 hours of hospitalization (early IV TCM) for AMI. 
Data come from the China Patient-centered Evaluative Assessment 
of Cardiac Events Retrospective Study of Acute Myocardial Infarction, 
restricted to a large, representative sample of Western medicine hospitals 
throughout China (n=162). We conducted a chart review of randomly 
sampled patients with AMI in 2001, 2006, and 2011, comparing early 
intravenous TCM use across years, predictors of any early intravenous 
TCM use, and association with in-hospital bleeding and mortality. From 
2001 to 2011, early intravenous TCM use increased (2001: 38.2% versus 
2006: 49.1% versus 2011: 56.1%; P<0.01). Nearly all (99%) hospitals 
used early intravenous TCM. Salvia miltiorrhiza was most commonly 
prescribed, used in one third (35.5%) of all patients admitted with AMI. 
Patients receiving any early intravenous TCM, compared with those 
who did not, were similar in age and sex and had fewer cardiovascular 
risk factors. In multivariable hierarchical models, admission to a 
secondary (versus tertiary) hospital was most strongly associated with 
early intravenous TCM use (odds ratio: 2.85; 95% confidence interval: 
1.98–4.11). Hospital-level factors accounted for 55% of the variance 
(adjusted median odds ratio: 2.84). In exploratory analyses, there were no 
significant associations between early intravenous TCM and in-hospital 
bleeding or mortality.
CONCLUSIONS: Early intravenous TCM use for AMI in China is increasing 
despite the lack of evidence of their benefit or harm. There is an urgent 
need to define the effects of these medications because they have 
become a staple of treatment in the world’s most populous country.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01624883
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Traditional Chinese medicine (TCM), a treatment approach that evolved over centuries to prevent and treat disease, incorporates herbal medicines 
and mind-body practices and remains an integral part of 
the Chinese healthcare system. Even as the healthcare 
market for Western therapies has expanded, so has the 
market for TCM.1 In 2011, $64 billion dollars was spent 
on TCM, an increase of ≈20% from 2008, with the 
greatest demand for TCM in the treatment of cardiac 
and cerebrovascular diseases.2 Despite the substantial 
increase in use, little is known about practice patterns 
for treating acute cardiovascular disease with TCM.
In China, the treatment of acute myocardial infarc-
tion (AMI) is mainly delivered in modern Western medi-
cine hospitals that emphasize conventional therapies 
(as opposed to traditional or integrative Chinese hos-
pitals that emphasize TCM); nonetheless, use of TCM 
among Western medicine hospitals is common.3 TCMs 
are reported to impact platelet aggregation, circulation, 
oxidative stress, vasoreactivity, and other cardiovascular 
properties,4,5 yet studies of the effectiveness of these 
agents are methodologically limited,4,6 and systematic 
reviews of TCM for cardiovascular disease have been 
inconclusive.5,7,8 In addition, although TCM has been 
used for centuries, there is no mention of TCM in the 
Chinese guidelines for treating AMI,9–11 which closely 
align with those from the United States and Europe. 
Thus, although TCMs are used in the care of patients 
with AMI, there is limited data about their use, with 
implications for disease management and outcomes. 
Specifically, we lack data on the types of TCM used to 
treat AMI and whether they are being used alone or in 
conjunction with conventional treatments.10,12–16
Accordingly, we used a nationally representative 
sample of patients with AMI admitted to Western med-
icine hospitals throughout China to investigate trends 
and outcomes associated with TCM, with a focus on 
intravenous therapies used in the first 24 hours (early 
intravenous TCM) to ensure that it was the intention 
of the providers to use TCM as opposed to patients 
supplementing their care with their own treatments. 
In addition, market data show that spending on intra-
venous TCM exceeds that of oral TCM for cardiovas-
cular disease management.2 Our primary aims were to 
(1) describe practice patterns in the use of early intra-
venous TCM across 3 study periods: 2001, 2006, and 
2011; and (2) assess patient and hospital-level charac-
teristics associated with early intravenous TCM use. In a 
secondary exploratory analysis, we assessed signals for 
harm and benefit by examining the association of early 
intravenous TCM with in-patient bleeding and mortal-
ity. Findings from this study are important for support-
ing quality improvement efforts in China that are sensi-
tive to the role of TCM as part of China’s history and 
culture and yet simultaneously commit to the safe and 
effective use of evidence-based approaches to improve 
outcomes for people with AMI.
METHODS
It is our goal to share the China PEACE-Retrospective AMI 
Study (China Patient-centered Evaluative Assessment of 
Cardiac Events Retrospective Study of Acute Myocardial 
Infarction) data; however, at this time, we are unable to do so.
Study Design, Setting, and Cohort
The China PEACE-Retrospective AMI Study was designed to 
assess trends in quality and outcomes of patients hospital-
ized with AMI during 3 different time periods in China: 2001, 
2006, and 2011.17 The study used a 2-stage approach to sam-
pling described in detail by Dharmarajan et al.17 Briefly, we first 
identified a nationally representative cohort of hospitals from 5 
regions, selected based on the 3 official economic-geographic 
regions of Mainland China (Eastern-rural, Central-rural, 
Western-rural, Eastern-urban, and Central/Western-urban). In 
WHAT IS KNOWN
• The use of traditional Chinese medicine to prevent 
and treat a broad range of conditions, including 
cardiovascular disease, is rapidly growing in China.
• Traditional Chinese medicine is being used in 
Western medicine hospitals for the treatment of 
acute myocardial infarction although limited data 
are available about the types of traditional Chi-
nese medicines used and whether they are used 
alone or as a complementary therapy.
• Chinese guidelines for the treatment of acute 
myocardial infarction are closely aligned with the 
US and European guidelines and do not discuss 
the use of traditional Chinese medicine.
WHAT THE STUDY ADDS
• In a large, nationally representative study of acute 
myocardial infarction care in Western medicine 
hospitals throughout China, use of traditional 
Chinese medicine for acute myocardial infarction 
increased from 2001 to 2011, with over half of 
patients treated with intravenous formulations of 
traditional Chinese medicine in the first 24 hours 
of hospitalization.
• Nearly all hospitals in the study used traditional 
Chinese medicine in at least some patients 
although secondary care hospitals (versus tertiary 
care hospitals) were more likely to use traditional 
Chinese medicine. Overall, hospital-level factors 
accounted for 55% of the variance.
• Traditional Chinese medicine was used in conjunc-
tion with guideline-based medical therapies and 
not as a stand-alone treatment.
• In this study, we did not find an association with 
in-hospital bleeding or mortality, although more 
research is needed.
Spatz et al; Traditional Chinese Medicine and AMI
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total, 175 modern Western medicine hospitals (a phrase used 
in China to designate hospitals that are based in Western or 
conventional therapies, distinguishing them from traditional 
and integrative hospitals) were sampled (105 rural and 70 
urban); 7 had no admissions for AMI and 6 declined to partici-
pate, resulting in a final cohort of 162 hospitals. In the second 
stage, systematic random sampling was used to identify hospi-
talizations with a principal diagnosis of AMI, defined through 
International Classification of Diseases—Clinical Modification 
codes versions 9 (410.xx) and 10 (I21.xx), or principal dis-
charge diagnosis terms noted in the medical record. From a 
total of 31 601 patients with AMI across the 3 study years, 
18 631 patients were sampled using systematic random sam-
pling procedures. After excluding patients with missing or 
illegible medical charts (n=524), patients not meeting study 
criteria (n=2007), patients transferred in or out (n=1930) of 
the current hospital, and AMIs of unknown type (ie, neither 
ST-segment–elevation myocardial infarction nor non–ST-seg-
ment–elevation myocardial infarction; n=73), the final cohort 
included 14 097 patients (Figure 1).
Medical charts were reviewed by a centralized data 
abstraction team using standardized data definitions. 
Rigorous quality standards were used, and 5% of medical 
records were randomly audited, with overall variable accu-
racy of >98%.17 Hospital characteristics were collected via an 
electronic questionnaire completed by investigators at each 
participating hospital.
Classification of TCM
Herbal medicines, including the name, route of adminis-
tration, and timing of use in the course of hospitalization, 
were abstracted from the medical record. Use of nonphar-
macological TCM (eg, qigong; acupuncture) for AMI is lim-
ited, if at all used, and therefore was not abstracted. Herbal 
medicines were classified into 6 main groups based on the 
primary active ingredient (Table I in the Data Supplement). 
The route of administration was categorized as either oral or 
intravenous, and timing of administration was categorized as 
either within first 24 hours or later. We focused on the most 
commonly used early intravenous TCMs (defined as being 
used in >5% of patients): Salvia miltiorrhiza; Folium ginkgo; 
and Panax notoginseng. TCMs that were infrequently used 
were combined into a category, labeled: Other TCM.
Covariates
We assessed the following variables, hypothesized to be 
associated with TCM use: year of AMI hospitalization; demo-
graphics (age and sex); clinical characteristics (presenting 
signs and symptoms; baseline cardiovascular risk factors and 
disease; AMI type and severity; and eligibility for reperfusion); 
clinical care management (pharmacological and reperfusion 
therapies—including receipt and timing of percutaneous 
coronary intervention [PCI] or fibrinolysis); and hospital-level 
characteristics (economic–geographic region; acuity status, 
ie, tertiary versus secondary; capacity to perform PCI; pres-
ence of coronary care unit). For variables with <1% missing, 
we imputed the values based on the most common values 
for categorical variables and the median value for continuous 
variables. For variables missing >1%, we created a dummy 
variable indicating missing and included it with the original 
variable in the adjusted models.
Outcomes
Patient outcomes were assessed in a composite measure of in-
hospital mortality or withdrawal from treatment. Withdrawal 
from treatment is a common disposition among patients 
deemed to be actively dying, but who do not want to die in the 
hospital; this disposition status was adjudicated by cardiologists 
in the coordinating study center. The outcome of in-hospital 
mortality or treatment withdrawal is used as a quality measure 
for hospitals by the Chinese government.18 We also assessed 
in-hospital bleeding given the antiplatelet effects of many of 
the TCMs and the potential for bleeding, especially if combined 
with other antiplatelet or anticoagulant use. Major bleeding 
was defined as any intracranial bleeding, an absolute decrease 
in hemoglobin of 5 mg/dL, bleeding resulting in hypovolemic 
shock, or fatal bleeding resulting in death within 7 days.
Statistical Analysis
We describe the frequency of early intravenous TCM use 
among patients admitted with AMI across the 3 study peri-
ods, including TCM type, timing of administration (propor-
tion administered in the first 24 hours of hospitalization), 
and potential cardiac effects for the most common TCMs 
used. Trends in early intravenous TCM were assessed with 
the Mann–Kendall test for continuous variables. We exam-
ined pairwise correlations to assess commonly used combina-
tions of the TCMs used in the first 24 hours; specifically, we 
calculated the frequency of use of each pair of the 4 TCMs 
and calculated the Pearson correlation coefficient to examine 
the association between each TCM pair. In addition, we com-
pared patient and hospital-level characteristics by the use of 
early intravenous TCM.
To identify factors associated with early intravenous TCM, 
we used hierarchical logistic regression models with backward 
stepwise selection of covariates, using a random effect at the 
hospital level to account for the patients’ clustering within 
hospitals. To assess whether early intravenous TCM was used 
Figure 1. The China PEACE (Patient-centered Evaluative 
Assessment of Cardiac Events) retrospective study of 
acute myocardial infarction: study flow chart.  
AMI indicates acute myocardial infarction.
Spatz et al; Traditional Chinese Medicine and AMI
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in lieu of evidence-based therapies, we assessed the bivari-
ate and multivariable association of early intravenous TCM 
with evidence-based, pharmacological therapies (aspirin, 
β-blocker, statin, heparin, clopidogrel, angiotensin-convert-
ing enzyme inhibitor/angiotensin receptor blocker), use of 
biomarker testing, cardiac catheterization, echocardiography, 
and reperfusion (PCI and fibrinolysis). To estimate the variabil-
ity in hospital-level early intravenous TCM use, we calculated 
the median odds ratio (OR) from the fully adjusted hierarchi-
cal model, which represents the average likelihood of a statis-
tically identical patient receiving early intravenous TCM at one 
random hospital versus another.
In exploratory analyses, we compared outcomes of patients 
receiving any early intravenous TCM, along with specific types 
of TCM using hierarchical logistic regression models adjusted for 
patients’ demographic and admission characteristics, medical 
history, diagnostic procedures, in-hospital medications and pro-
cedures, and hospital characteristics. This study was approved by 
the institutional review boards of Yale University and the Fuwai 
Hospital, National Center for Cardiovascular Disease in China.
RESULTS
Utilization Patterns of Early Intravenous 
TCM
Among the 14 097 patients admitted with AMI across 
the 3 time periods (representing 223 286 patients with 
AMI in 2011), two thirds (n=9424; 66.9%) received 
either oral or intravenous TCM during hospitalization, 
among which 77% was administered intravenously 
within the first 24 hours of hospitalization (Table  1; 
Table II in the Data Supplement). Use of early intra-
venous TCM increased significantly across the 3 time 
periods: 38.2% in 2001 versus 49.1% in 2006 versus 
56.1% in 2011; P<0.001. Among hospitals enrolled 
in 2011 (n=162), all but 2 hospitals administered early 
intravenous TCM.
The most commonly used early intravenous TCMs 
were Salvia miltiorrhiza (danshen), used in one third 
(35.5%) of all patients admitted with AMI, followed 
by Panax notoginseng (12.2%); Folium ginkgo (7.5%); 
puerarin (2.7%); and breviscapinun (2.2%). Nine per-
cent of patients received ≥2 types of early intravenous 
TCM, with the most common combinations being Sal-
via miltiorrhiza (danshen) with either Panax notogin-
seng (4.0%) or Folium gingko (2.5%).
Characteristics of Patients Receiving  
Early Intravenous TCM
Characteristics of patients who did and did not receive 
early intravenous TCM are compared in Table 2. The 
mean age of patients was similar (65.3 years [SD: 
12.4] versus 65.2 years [SD: 12.6]), and there were 
no sex differences (% female: 30.9% versus 32.0%). 
Statistically significant, but clinically modest differenc-
es in baseline characteristics were observed. Patients 
receiving any early intravenous TCM were less likely 
to have a prior diagnosis of angina or coronary heart 
disease (21.9% versus 23.8%), prior AMI (9.8% ver-
sus 11.8%), or to have hypertension, diabetes mel-
litus, hyperlipidemia, or be active smokers at baseline. 
Table 1. Trends in Early intravenous TCM Use Among Patients Treated for AMI in Western 
Medicine Hospitals in China
Description
Total 2001 2006 2011
P Valuen % n % n % n %
All 14 097 100.00 2101 100.00 4026 100.00 7970 100.00  
Any TCM
  In hospital 9424 66.85 1222 58.16 2608 64.78 5594 70.19 <0.001
  IV In hospital 8664 61.46 1060 50.45 2398 59.56 5206 65.32 <0.001
  Within 24 h 7964 56.49 945 44.98 2172 53.95 4847 60.82 <0.001
  IV within 24 h 7251 51.44 802 38.17 1976 49.08 4473 56.12 <0.001
Salvia miltiorrhiza (danshen)
  IV within 24 h 5004 35.50 603 28.70 1298 32.24 3103 38.93 <0.001
Folium ginkgo
  IV within 24 h 1063 7.54 6 0.29 333 8.27 724 9.08 <0.001
Panax notoginseng
  IV within 24 h 1717 12.18 129 6.14 379 9.41 1209 15.17 <0.001
Breviscapinun
  IV within 24 h 312 2.21 66 3.14 111 2.76 135 1.69 <0.001
Puerarin
  IV within 24 h 374 2.65 68 3.24 181 4.50 125 1.57 <0.001
AMI indicates acute myocardial infarction; and TCM, traditional Chinese medicine.
Spatz et al; Traditional Chinese Medicine and AMI
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Table 2. Baseline Characteristics Stratified by Use of Intravenous TCM Within 24 Hours
Description
Total
Early Intravenous 
TCM: Yes
Early Intravenous 
TCM: No
P for 
Differencen % n % n %
All 14 097 100 7251 100 6846 100  
Demographics
  Year       <0.001
   2001 2101 14.90 802 11.06 1299 18.97  
   2006 4026 28.56 1976 27.25 2050 29.94  
   2011 7970 56.54 4473 61.69 3497 51.08  
  Age: mean (SD) 65.23 12.46 65.29 12.35 65.16 12.57 0.553
  Age: categories       0.218
   <55 y 2936 20.83 1487 20.51 1449 21.17  
   55 to < 65 y 3253 23.08 1710 23.58 1543 22.54  
   65 to <75 y 4299 30.50 2173 29.97 2126 31.05  
   75 y or older 3609 25.60 1881 25.94 1728 25.24  
  Female       0.184
   Yes 4430 31.43 2242 30.92 2188 31.96  
Admission characteristics
  ST segment–elevation myocardial infarction 12 108 85.89 6316 87.11 5792 84.6 <0.001
  Chest discomfort       0.029
   Yes 12 877 91.35 6663 91.89 6214 90.77  
   No 885 6.28 436 6.01 449 6.56  
  Symptom onset to hospitalization, h       <0.001
   <3 2657 18.85 1494 20.6 1163 16.99  
   3 to <15 4424 31.38 2365 32.62 2059 30.08  
   15 to <72 2916 20.69 1471 20.29 1445 21.11  
   ≥72 4100 29.08 1921 26.49 2179 31.83  
  Cardiogenic shock on presentation 816 5.79 479 6.61 337 4.92 <0.001
  Pneumonia at presentation 1447 10.26 666 9.18 781 11.41 <0.001
  COPD exacerbation on presentation 249 1.77 125 1.72 124 1.81 0.694
  Acute stroke on presentation 181 1.28 108 1.49 73 1.07 0.026
  MiniGRACE score
   Unknown 983 6.97 486 6.7 497 7.26 0.194
   Mean (SD) 138.55 27.42 139.51 27.51 137.53 27.29 <0.001
Physical examination on admission
  Heart rate (HR): mean bpm (SD) 78.82 21.72 77.73 21.68 79.98 21.71 <0.001
  HR: categories, bpm       <0.001
   HR<60 1778 12.61 1027 14.16 751 10.97  
   60–90 9057 64.25 4669 64.39 4388 64.1  
   HR>90 3262 23.14 1555 21.45 1707 24.93  
  Systolic blood pressure: mean (SD) 127.96 30.69 125.71 30.83 130.33 30.36 <0.001
  Systolic blood pressure: categories, mm Hg       <0.001
   <100 1631 11.57 994 13.71 637 9.3  
   100–160 10 942 77.62 5566 76.76 5376 78.53  
   >160 1524 10.81 691 9.53 833 12.17  
  Diastolic blood pressure: mean (SD) 78.85 21.40 77.93 21.03 79.82 21.75 <0.001
(Continued )
Spatz et al; Traditional Chinese Medicine and AMI
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On presentation, patients receiving early intravenous 
TCM were more likely to present with ST-segment–
elevation myocardial infarction (87.1% versus 84.6%) 
and within 3 hours of symptom onset (20.6% ver-
sus 17.0%); they were less likely to present after 72 
hours of symptom onset (26.5% versus 31.8%). Mean 
presenting systolic blood pressure was lower among 
people receiving early intravenous TCM (126 versus 
130 mm Hg). Patients receiving early intravenous 
TCM were more likely to present in cardiogenic shock 
(6.6% versus 4.9%).
Bivariate analyses revealed that in-hospital man-
agement differed between patients receiving early 
intravenous TCM and patients who did not (Table 3). 
Although there were no differences in reperfusion 
rates (30.2% versus 30.6%), there were significant 
unadjusted differences in the types of reperfusion 
among the 2 groups, with fewer primary PCI (6.3% 
versus 15.0%) and more fibrinolysis therapy (23.9% 
versus 15.6%) in the early intravenous TCM group. 
Comparing early intravenous TCM with no early intra-
venous TCM, more patients received aspirin (88.4% 
versus 82.9%), statin (71.3% versus 63.2%), and 
heparin (80.3% versus 69.9%), with no difference in 
angiotensin-converting enzyme inhibitor/angiotensin 
receptor blocker (47.8% versus 48.5%), clopidogrel 
(56.4% versus 54.8%), or β-blocker (46.3% versus 
47.2%).
Patient and Hospital Characteristics 
Associated With Early Intravenous TCM 
Administration
Although nearly all of the sampled hospitals used early 
intravenous TCM in at least some patients with AMI, 
there were significant differences in the magnitude of 
patients receiving early intravenous TCM among differ-
ent hospitals (mean, 63.0%; SD, 24.1%; Table 4). Cer-
tain hospital characteristics were associated with greater 
use of early intravenous TCM (Figure 2). Secondary hos-
pitals administered more early intravenous TCM than 
tertiary hospitals (mean use in 2011: 71.4%; SD 22.8% 
versus 55.3%; SD, 27.7%). Early intravenous TCM was 
also used more commonly in nonteaching (68.4%; SD, 
23.8%) versus teaching hospitals (62.1%; SD, 27.4%), 
non-PCI (69.5%; SD, 22.1%) versus PCI hospitals 
(58.9%; SD, 29.2%), rural (68.7%; SD, 24.4%) versus 
urban hospitals (58.5%; SD, 27.6%), and among hos-
pitals in the Central (69.7%; SD, 19.8%) and Western 
(69.0%; 25.8%) regions, as compared with the Eastern 
region (57.6%; SD, 29.3%).
In hierarchical logistic regression models, patient 
factors were not strongly associated with early intra-
venous TCM (Table III in the Data Supplement). How-
ever, patients treated in secondary hospitals were more 
likely to receive early intravenous TCM than patients 
treated in tertiary hospitals (OR: 2.85; 95% confidence 
  Diastolic blood pressure: categories, mm Hg       <0.001
   <60 1079 7.65 646 8.91 433 6.32  
   60–100 11 857 84.11 6042 83.33 5815 84.94  
   >100 1161 8.24 563 7.76 598 8.74  
Medical history
  Angina or coronary heart disease 3215 22.81 1586 21.87 1629 23.79 0.007
  Myocardial infarction 1516 10.75 710 9.79 806 11.77 <0.001
  PCI/CABG/fibrinolysis 349 2.48 134 1.85 215 3.14 <0.001
  Heart failure* 254 1.80 112 1.54 142 2.07 0.018
  Smoking 4640 32.91 2306 31.8 2334 34.09 0.004
  Hypertension 6995 49.62 3355 46.27 3640 53.17 <0.001
  Diabetes mellitus history 2465 17.49 1118 15.42 1347 19.68 <0.001
  Dyslipidemia 656 4.65 248 3.42 408 5.96 <0.001
  Stroke 1647 11.68 814 11.23 833 12.17 0.082
  Chronic lung disease 643 4.56 326 4.5 317 4.63 0.702
  Hepatitis or hepatitis infection 291 2.06 134 1.85 157 2.29 0.063
CABG indicates coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; miniGRACE, mini Global Registry of Acute Coronary 
Event score; PCI, percutaneous coronary intervention; and TCM, traditional Chinese medicine.
*Ventricular tachycardia or fibrillation, and atrial fibrillation or flutter, permanent pacemaker, and automatic implantable cardioverter defibrillator 
are included.
Table 2. Continued
Description
Total
Early Intravenous 
TCM: Yes
Early Intravenous 
TCM: No
P for 
Differencen % n % n %
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interval: 1.98–4.11). Overall, we observed substantial 
variation in the use of early intravenous TCM across 
hospitals (median OR=2.84), suggesting that the aver-
age odds of a patient receiving early intravenous TCM 
at one random hospital versus another varied ≈3-fold 
after adjusting for patient and treatment characteris-
tics (Table III in the Data Supplement). Fifty-five percent 
(55%) of the variance in use of early intravenous TCM 
among patients was explained by the nested effect (or 
clustering) of patients among hospitals (intra-class cor-
relation: 0.55).
Association of Early Intravenous TCM 
With In-Patient Outcomes
Patients receiving early intravenous TCM, compared 
with those who did not, had slightly lower rates of in-
hospital bleeding (6.2% versus 7.4%, P<0.01; OR and 
95% confidence interval: 0.82 [0.72, 0.94]) and similar 
rates of in-hospital mortality or treatment withdrawal 
(11.8% versus 11.0%, P=0.14; OR and 95% confidence 
interval: 1.08 [0.98, 1.20]). In the fully adjusted hierar-
chical models, there was no association with receipt of 
Table 3. Clinical Management Stratified by Use of Intravenous TCM Within 24 Hours
Description
Total
Early Intravenous 
TCM: Yes
Early Intravenous 
TCM: No
P for 
Differencen % n % n %
All 14 097 100.00 7251 100 6846 100  
Diagnostic tests
  ECG at presentation to hospital 11 988 85.04 6191 85.38 5797 84.68 0.241
  Chest x-ray 755 5.36 361 4.98 394 5.76 0.041
  Echocardiography 7196 51.05 3459 47.7 3737 54.59 <0.001
Echocardiography ejection fraction (EF) value
  Unknown 7486 53.10 4082 56.3 3404 49.72 <0.001
  Mean (SD) 53.73 11.99 54.23 12.3 53.27 11.67 0.001
Echocardiography EF value: categories       <0.001
  Unknown 7486 53.10 4082 56.3 3404 49.72  
  <35 426 3.02 205 2.83 221 3.23  
  35≤EF≤70 5763 40.88 2734 37.71 3029 44.24  
  EF>70 422 2.99 230 3.17 192 2.8  
Cardiac catheterization
  Cardiac catheterization 3561 25.26 1458 20.11 2103 30.72 <0.001
  Primary percutaneous coronary 
intervention (PCI)
3057 21.69 1247 17.2 1810 26.44 <0.001
  Refusal of PCI 1079 7.65 489 6.74 590 8.62 <0.001
  Guidewire crossed lesion 2697 19.13 1105 15.24 1592 23.25 <0.001
Laboratory data
  Troponin 7205 51.11 3515 48.48 3690 53.9 <0.001
  Any biomarker 13 114 93.03 6765 93.3 6349 92.74 0.194
Reperfusion therapies
  Reperfusion 4284 30.39 2188 30.18 2096 30.62 0.569
  Primary PCI 1485 10.53 458 6.32 1027 15 <0.001
  Fibrinolytic therapy 2799 19.86 1730 23.86 1069 15.61 <0.001
Medications within 24 h
  Aspirin 12 088 85.75 6411 88.42 5677 82.92 <0.001
  Heparin 10 612 75.28 5825 80.33 4787 69.92 <0.001
  Clopidogrel 7846 55.66 4092 56.43 3754 54.83 0.056
  β-Blockers 6584 46.70 3354 46.26 3230 47.18 0.271
  Statins 9495 67.35 5170 71.30 4325 63.18 <0.001
  ACEi/ARB 6785 48.13 3467 47.81 3318 48.47 0.439
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and TCM, traditional Chinese medicine.
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early intravenous TCM and in-patient bleeding or with 
mortality or treatment withdrawal (Table 5). Outcomes 
by type of TCM were examined both in unadjusted and 
multivariable hierarchical models, and there was no sig-
nificant associations between use of Salvia miltiorrhiza, 
Folium gingko, Panax notoginseng, other early intrave-
nous TCM or >1 early intravenous TCM with in-hospital 
bleeding, mortality, or treatment withdrawal (Tables 
intravenous and V in the Data Supplement).
DISCUSSION
In this nationally representative study, over half of 
patients hospitalized with AMI in modern Western 
medicine hospitals in China received intravenous TCM 
within the first 24 hours of hospitalization, a 20% abso-
lute increase from 2001. Use of TCM was largely a func-
tion of hospital practice. Although early intravenous 
TCM was used in nearly all hospitals, secondary hos-
pitals (often without PCI capability and located in rural 
regions) were more likely to use TCM. Still, about half 
of patients cared for in tertiary hospitals, and two thirds 
of patients cared for in teaching hospitals received early 
intravenous TCM. We did not observe differences in use 
of early intravenous TCM based on patient characteris-
tics. We also did not find evidence that TCM was being 
used in lieu of evidence-based therapies; instead, our 
findings suggest that TCM is used as a complementary 
therapy in the early management of AMI. Use of TCM 
as a complementary therapy varied by hospital. Specifi-
cally, patients with statistically identical characteristics 
and clinical management, on average, were ≈3× more 
likely to receive early intravenous TCM at some hospi-
tals versus others. Finally, in an exploratory analysis, we 
did not observe signals of harm or benefit with respect 
to in-hospital bleeding and in-patient mortality or treat-
ment withdrawal. Our findings are consistent with larg-
er national trends showing an increase in use of TCM 
for all diseases throughout China and reflect a complex 
culture in medicine that simultaneously encourages 
Table 4. Hospital Characteristics Stratified by Use of intravenous TCM Within 24 
Hours
Description
Total
Early intravenous 
TCM: Yes
Early intravenous 
TCM: No
P for 
Differencen % n % n %
All 14 097 100.00 7251 100 6846 100  
Hospital characteristics
  Acuity       <0.001
   Secondary hospital 4790 33.98 3168 43.69 1622 23.69  
   Tertiary hospital 9307 66.02 4083 56.31 5224 76.31  
  Region       <0.001
   Eastern 8415 59.69 3749 51.7 4666 68.16  
   Central 2988 21.20 1857 25.61 1131 16.52  
   Western 2694 19.11 1645 22.69 1049 15.32  
   Urban 8812 62.51 3939 54.32 4873 71.18 <0.001
  Teaching hospital 11 482 81.45 5604 77.29 5878 85.86 <0.001
  PCI hospital 8729 61.92 4009 55.29 4720 68.95 <0.001
PCI indicates percutaneous coronary intervention; and TCM, traditional Chinese medicine.
Figure 2. Hospital characteris-
tics associated with use of early 
intravenous traditional Chinese 
medicine in patients with acute 
myocardial infarction in 2011.
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adherence to guidelines based on conventional treat-
ment of AMI, including primary revascularization and 
medical therapy, along with integration of TCM.11,19,20
TCM has been an integral part of medicinal heal-
ing in China for centuries. In the 1950s, to preserve 
the tradition of TCM, the Chinese government invest-
ed in studies of TCM, and in 1958, they declared that 
TCM would be given support equal to that of Western 
medicine.14 However, with the emergence of evidence-
based approaches for treating AMI in the 1980s and 
early 1990s, we expected to find a decline in the use 
of TCM, especially among Western hospitals in China 
which follow guidelines that are similar to the United 
States and Europe. In contrary, our data reveal that in 
a contemporary period, the use of TCM has increased. 
The rise in use may reflect even more government 
investment in preserving TCM, including more research 
on the effectiveness of TCM as well as broad insurance 
coverage for intravenous TCMs, which may influence 
the public’s perceptions about the benefits and safety 
of TCM.14 Several recent studies published in the Chi-
nese literature and in complementary medicine journals 
show improved biological and clinical outcomes, includ-
ing improved angiographic coronary blood flow and 
reflow,21,22 decreased stent restenosis, shorter hospital 
stays, less angina,23 fewer readmissions,23 improved 
quality of life, and improved short- and long-term mor-
tality.5,24 In the case of Salvia miltiorrhiza/danshen, the 
most widely used TCM, there are reports of superior 
efficacy and fewer side effects than nitroglycerin for 
the treatment of angina.25 As such, Salvia miltiorrhiza/
danshen may be more acceptable to and well tolerated 
by patients with angina. It is also one of 200+ TCMs 
included on the National Essential Drugs list, started in 
2000 and last updated in 2017, which are made widely 
available at no or little cost. In fact, all of the TCMs 
that we observed to be in use were listed as class A or 
class B drugs, which are covered by insurance at 100% 
and 70% to 80% of cost, respectively. Nonetheless, at 
least 2 Cochrane reviews along with other systematic 
reviews have rendered the evidence either negative 
or inconclusive to support the use of TCM, including 
the use of Salvia miltiorrhiza/danshen for angina or 
coronary artery disease.8,26,27 Moreover, TCM is a small 
part of the curriculum of conventional Chinese medi-
cal schools, and use of Salvia miltiorrhiza/danshen to 
treat angina and other TCMs for the management of 
AMI are not recommended in Chinese clinical practice 
guidelines.10
Several observations suggest that hospital capacity 
may have played a role in the use of TCM. Hospitals 
without PCI capability and presumptively fewer resourc-
es were more likely to use TCM. Consistent with this, 
patients who received TCM were less likely to have 
undergone PCI although more likely to have received 
fibrinolysis. They were also less likely to have received 
an echocardiogram or a diagnostic cardiac catheteriza-
tion. Local culture, at the hospital and of the region, 
may have also played a role. Secondary hospitals and 
hospitals located in the Central and Western regions of 
the country, which are typically poorer and tend to be 
less westernized, were more likely to use TCM.28
Importantly, we did not find evidence of TCM being 
used as a substitute for evidence-based therapies. For 
example, patients receiving early intravenous TCM 
were more likely to also receive aspirin and heparin in 
the first 24 hours and just as likely to receive clopido-
grel and β-blocker therapy as compared with patients 
not receiving early intravenous TCM. Collectively, these 
findings suggest that TCM is not a last resort therapy; it 
does not seem to be used as a salvage therapy or as a 
replacement for conventional therapies, but rather, as a 
complementary therapy that is part of hospital culture 
in the treatment of AMI.
Several limitations should be considered in the inter-
pretation of these findings. The classification of TCM 
assumed similar preparations and doses although there 
is likely substantial heterogeneity, and we did not cap-
ture prehospital usage. Nonetheless, the overwhelm-
ing majority of TCMs could be categorized into 1 of 5 
main ingredients, with the majority of hospitals (87%) 
using Salvia miltiorrhiza/danshen in the first 24 hours 
of hospitalization, demonstrating a common approach 
to practice. Second, our approach to examining factors 
associated with TCM was based on data from a ret-
rospective review of medical records, which may not 
capture the full spectrum of patient, physician, or hos-
pital characteristics that might influence use of TCM. 
Third, our work examining associations of TCM with 
in-hospital outcomes is exploratory. Doses and formula-
tions of intravenous TCM were not standardized, and 
we may not have had adequate power to exclude a 
clinically important association. In addition, the asso-
ciation of TCM with other short- and long-term out-
comes, such as recurrent AMI, revascularization, and 
stroke, are important to assess. Ultimately, randomized 
trials would provide the most definitive evidence of the 
safety and efficacy of TCM. Fourth, our study is limited 
Table 5. In-Hospital Events Stratified by Use of 
Intravenous TCM Within 24 Hours
Description
Total
Early 
Intravenous 
TCM: Yes
Early 
Intravenous 
TCM: No
P for 
Differencen % n % n %
In-hospital 
bleeding
961 6.82 451 6.22 510 7.45 0.004
In-hospital 
mortality or 
treatment 
withdrawal
1608 11.41 855 11.79 753 11 0.139
TCM indicates traditional Chinese medicine.
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to China although the sample is representative of the 
care of a country with a fifth of the world’s population.
In conclusion, early intravenous TCM for the manage-
ment of AMI occurs in modern Western medicine hos-
pitals throughout China. Many types of TCM are used 
although the predominant formulation was with Salvia 
miltiorrhiza/danshen, touted for its properties as a vaso-
dilator and anticoagulant. Although nearly all hospitals in 
our sample used early intravenous TCM, the proportion 
of patients treated varied by hospital but not by patient 
characteristics. Given the overall high use, there is an 
urgent need for the study of the safety and effectiveness 
of early intravenous TCM strategies in patients with AMI.
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